Weight regain after stopping GLP-1 medication

Weight regain after stopping is one of the most common questions people have about Wegovy, Ozempic, Mounjaro, or a similar medication. If you've come off treatment, or you're thinking about stopping, you've probably heard the word "rebound."

This guide explains why regain happens, what the evidence says about how common it is, and what support is available through the NHS and private routes if you want help managing the transition.

GLP-1 medications work by copying a hormone your body makes naturally after eating. This hormone tells your brain you're full, slows down how fast food leaves your stomach, and reduces cravings. 

When you stop taking the medication, that effect fades as the drug clears your system, usually over several weeks. Your hunger signals tend to move back towards how they were before treatment. For most people, the underlying drivers of weight gain, appetite, metabolism, and food environment, haven't changed, only the medication had changed them.

Weight regain after stopping isn't a sign the medication "didn't work" or that you did something wrong. It reflects how appetite-regulating hormones behave once treatment ends. There's ongoing debate among clinicians and researchers about how best to think about obesity long-term: some emphasise it as a condition that may need ongoing management, others place more weight on lifestyle and environmental factors. There's no single agreed view, and what's right for you is a decision to make with a clinician.

Clinical trial data gives us the clearest picture of what tends to happen after stopping semaglutide (Wegovy, Ozempic) or tirzepatide (Mounjaro), though real-world results vary from person to person and trial findings don't always translate directly to everyday use.

In a follow-up to the STEP 1 trial, people who stopped semaglutide had regained around two-thirds of the weight they'd lost within a year of stopping. A separate 2026 analysis of several trials estimated that regain eventually levels off at around three-quarters of the weight originally lost. This pattern is sometimes called GLP-1 rebound weight gain. Regain tends to be fastest in the first few months after stopping, then slows down over time, though not every trial has shown the same pattern.

How much comes back varies from person to person, and depends on factors including how long you were on treatment, lifestyle changes made during treatment, whether medication is restarted, and ongoing support after stopping. Some regain is common, but full regain to your starting weight is not inevitable, and people's experiences vary widely.

People sometimes assume that tapering the dose down gradually, rather than stopping in one go, will prevent regain. UK guidance doesn't currently recommend a taper specifically to prevent weight regain, and this hasn't been directly studied. Whether to reduce the dose gradually or stop at your current dose is a decision for your prescriber, based on your individual circumstances.

Guidance on stopping semaglutide and tirzepatide mainly focuses on continuing support after treatment ends, rather than on how the dose is brought down.

The table below sets out the two approaches people commonly discuss with a prescriber. It's for background only, not a recommendation.

The UK medicines regulator, the MHRA, has issued guidance relevant to anyone taking or considering GLP-1 medication, including:

If you experience severe abdominal pain, persistent vomiting, or other symptoms that concern you, contact your GP, NHS 111, or your private prescriber promptly. This is general safety information, not a full list of side effects, so read the patient information leaflet that comes with your medication, and speak to a health professional about any symptoms you're worried about.

If you were prescribed a GLP-1 medication through the NHS, support for coming off it should be part of your original care plan, though in practice this varies by area.

NICE guidance recommends that people stopping weight-management medication get ongoing feedback and monitoring for at least a year afterwards, to help support any changes they want to maintain. In practice, how this is delivered varies between areas.

NHS support may include:

It's worth being honest about where the gaps are. Specialist NHS weight management services (sometimes still called Tier 3 or Tier 4 services) have limited capacity in many areas, and how long you wait for a review or follow-up appointment can vary significantly depending on where you live. If you're not offered a follow-up plan when your prescription ends, you can ask your GP practice for one directly, you do not need to manage the transition alone. If you were treated through an NHS specialist service, ask what aftercare is included before your treatment course ends.

If you were treated privately, aftercare isn't always included automatically, so it's worth checking what your provider offers before you stop.

Private support options may include:

Costs vary widely between providers, and ongoing support is usually charged separately from the medication itself. Private prices aren't set or capped by any UK regulator, and they change over time, so check current pricing directly with any provider you're considering. If a private provider prescribed your medication, ask them directly what happens at the end of your course, some build in a review consultation, others don't unless you request one.

There's no fixed rule for when regain means you should restart medication. It depends on your individual health, how much weight has come back, and how it's affecting you.

Some people find it helpful to book a review with a GP or their prescriber if they're concerned about regain, unsure what their options are, or were told at the start of treatment that ongoing or repeat courses might be part of their plan. A clinician is best placed to assess whether regain is affecting your health or wellbeing in a way that's relevant to your care.

A clinician can help you weigh up whether restarting, switching medication, or trying a different kind of support makes more sense for you. This decision should always be made with a prescriber, not on your own.

Restarting a GLP-1 medication after a break isn't automatic. NHS access is based on eligibility criteria such as BMI and related health conditions, and these are checked again at any new referral or prescription. Private prescribers will usually want to reassess you too before prescribing again. If you previously stopped because of confirmed pancreatitis, current safety guidance says treatment should not be restarted. NHS access to these medications is also changing: eligibility rules, funding, and which services prescribe them are being updated through 2026, so it's worth checking current criteria with your GP or ICB rather than relying on older information.

Information in this guide is based on publicly available guidance and published trial data. Sources referenced include: